1 The interaction between cyclosporin (CyA) and erythromycin was studied in renal transplant patients following oral and intravenous administration of CyA. 2 Blood and plasma CyA concentrations and blood concentrations of metabolite 17 were measured by h.p.l.c. 3 Erythromycin produced almost a two-fold increase in bioavailability, from 36% to 60%; with a small (13%) decrease in clearance of CyA. 4 The metabolite 17 data further support the postulate that erythromycin increases the absorption of CyA rather than inhibits its metabolism, as generally believed.
Introduction
Methods Ptachcinski et al. (1985) appear to have been the first to report an increase in the blood cyclosporin (CyA) trough concentration following coadministration of oral erythromycin. As the therapeutic index of CyA is narrow, such an interaction may predispose the patient to increased toxicity. Several workers (Gonwa et al., 1986; Martell et al., 1986; Wadhwa et al., 1987a) have subsequently confirmed the interaction. In most of these reported studies, CyA was administered orally only. However, following oral CyA administration, an increased concentration can be due to either increased absorption, reduced clearance or both effects. If clearance is reduced, then the disposition kinetics of CyA following i.v. administration should be affected. The aim of the present study was to elucidate further the erythromycin-CyA interaction by giving CyA both orally and intravenously in the absence and presence of erythromycin. The conclusions are based on h.p.l.c. analysis of CyA and of one of its major metabolites, No. 17 (M-17) . Our preliminary findings were published recently (Gupta et al., 1988) .
Clinical
Six renal transplant patients (five male and one female), 6 to 12 months post renal transplantation, stabilised on oral CyA therapy for 6-12 months were studied. All had satisfactory renal function. The dose of CyA differed among the patients, but remained the same for each during the study period. The intravenous dose of CyA was set at 70% of the oral dose, assuming an oral bioavailability of 70% (Gupta et al., 1987a) . The study was divided into two phases, A and B, and was carried out over 5 consecutive days with the patients confined throughout in an investigational unit. In Phase A (days 1 and 2) CyA was administered alone. In Phase B (days 4 and 5) patients received both CyA and erythromycin. The oral regimen of erythromycin, comprising erythromycin base (500 mg) administered at 6, 12, 18 and 24 h was commenced on day 3 and continued throughout days 4 and 5. On each study day (1, 2, 4, 5) a single dose of CyA was administered at 09.00 h either orally or intravenously, in a randomised 476 S. K. Gupta et al. order to different patients. However, the order of administration for a patient was kept the same in both the phases. A single oral dose of CyA was administered at 09.00 h on day 3.
The oral dose of CyA was prepared by transferring the required amount of CyA into a 100 ml bottle, to which was added the contents of a sachet of Caotina chocolate powder (Wander) and the bottle shaken vigorously. Semiskimmed milk (100 ml) was then added and the bottle again shaken vigorously, whereupon a relatively stable emulsion was formed. Patients swallowed the emulsion immediately after preparation. Blood samples (7 ml) were collected in tubes containing potassium EDTA immediately before and at 1, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h post dosing. The intravenous dosing solution was prepared by adding two ampoules of the intravenous preparation of CyA (Sandoz, 50 mg ml -1) into a plastic bag containing 100 ml normal saline. The volume of solution, containing the calculated intravenous dose of CyA, was infused via a peripheral arm vein at a constant rate over a 3-6 h period, using a calibrated infusion pump (IMED 365). Blood samples (7 ml) were collected from the opposite arm, just before and at 1,2, 3,5, 6, 6.5,7, 9, 11, 15 and 24 h after starting the infusion.
During the study no patient received any medication reported to interact with CyA. The study protocol was approved by a local ethics committee and written consent was obtained from each patient before commencing the study.
CyA and M-1 7 concentration measurements Plasma was separated at 370 C. CyA was measured in blood and plasma by h.p.l.c. (Gupta et al., 1987b 
In this equation C(t) is the plasma concentration at time t since starting the infusion; Ro is the infusion rate, V1 is the initial volume of distribution; Cl' is the fraction of the initial (zero time) plasma concentration associated with the first exponential coefficient, had an i.v. bolus of unit dose been given; Al, \2 are the exponential coefficients associated with the first and second exponential terms, respectively. C(O) is the concentration at the beginning of the infusion. The value 0 assumes the value of t during the infusion and of T, the duration of the infusion, after stopping the infusion. The equation was fitted to the data using nonlinear extended least squares regression analysis (Sheiner & Beal, 1981) .
The volume of distribution at steady state (V.,) was estimated from the disposition parameters in the standard manner (Gibaldi & Perrier 1982) . The oral bioavailability of CyA (F) was estimated using Equation 2,
where CL is the plasma clearance associated with the particular phase, control or erythromycin treatment, and AUC is the corresponding total area for CyA in plasma obtained after an oral dose.
The cumulative amount of CyA absorbed with time was assessed using a modified Loo- (Rowland & Gupta, 1987) , leading to some potential errors in estimating the total AUC of M-17. Nonetheless, the results of the study are sufficient to lead to some reasonably firm conclusions. Both blood and plasma CyA data are reported, but only the plasma data are used here for pharmacokinetic analysis. The blood data were not used because of the known saturable binding of CyA to erythrocytes, which can confound quantitative interpretation of the resultant pharmacokinetic parameters (Legg et al., 1987) . The blood CyA measurements were included for comparative purposes because in most of the previous erythromycin-CyA interaction studies blood CyA data only are reported (Freeman et al., 1987; Hourmant et al., 1985; Aoki et al., 1987) . Our blood data confirm the earlier findings of an increase in both Cmax and AUC but no change in terminal half-life, when coadministering erythromycin with oral CyA.
Metabolite 17 was measured because this is one of the major metabolites of CyA (Maurer et al., 1984) . Blood M-17 data are reported because this metabolite preferentially binds to erythrocytes (Rosano et al., 1986) such that the plasma concentration is below the detection limit of the h.p.l.c. assay employed. Because of the anticipated non-linearity of the erythrocytic binding, the metabolite data are used primarily as a guide to distinguish between some of the possible mechanisms of the erythromycin-CyA interaction. Erythromycin is an inhibitor of cytochrome P-450-3c, the enzyme system reported to be predominantly responsible for CyA metabolism (Bertault Peres et al., 1987) . Thus, the CyAerythromycin interaction is generally believed to be due to inhibition of CyA metabolism. However, the intravenous CyA data does not strongly support this hypothesis. Although there is a decrease in CyA clearance, it is marginal at best. Also there is little change in the AUC of M-17 after intravenous CyA administration; a large decrease in AUC might be expected if a significant degree of inhibition of CyA metabolism had occurred. Possibly the lack of change in the disposition kinetics of CyA arises because erythromycin was administered for only 24 h before starting the interaction phase. It was argued, however, that with a half-life of erythromycin of 2-3 h (Ludden, 1985) , 24 h should be long enough to ensure establishment of a plateau of erythromycin in the body and to produce a definitive effect. Certainly, there is little evidence to indicate that the situation is materially different after more prolonged periods of erythromycin administration. Thus, Aoki et al. (1987) observed only a 25% decrease in the CyA clearance in three out of four patients studied, following 21 days of oral dose of erythromycin therapy. In addition both Wadhwa et al. (1987a) and Freeman et al. (1987) reported that, although there is an increase in oral AUC, there is no change in the terminal half-life of CyA following erythromycin administration. CyA is a drug of low to moderate clearance with an extraction ratio of 0.2 to 0.35 (Beveridge et al., 1981; Venkataramanan et al., 1985) , and for such a drug inhibition of the metabolism should have resulted in an increase in the terminal half-life.
All the data point to erythromycin primarily increasing the oral bioavailability of CyA, from 36 to 60%. The mechanism for this increased absorption is unclear. Perhaps the usually low oral bioavailability of CyA is due to extensive first pass (pre-hepatic and/or hepatic) metabolism and that erythromycin reduces this effect, but there is little evidence to support this hypothesis. A significant first-pass hepatic loss of CyA may be discounted as CyA is a drug of only low clearance (0.30 1 h-1 kg-) compared with hepatic blood flow (1.3 1 h -kg -l). Also there is no definitive evidence of pre-hepatic CyA metabolism.
The proportional two-fold increase in AUC of M-17 with that of CyA, with no significant change in the AUC(m)/AUC ratio, following oral administration before and during erythromycin administration (1.41 vs 1.49; Table 2 ), further supports the hypothesis that the mechanism involved is one of increased input of CyA into the body rather than a decrease in its metabolism. Had the clearance of either drug, metabolite, or both changed then the equality of area ratios would no longer hold (Rowland & Gupta, 1987 (Table 3 ). As seen from the cumulative absorption plots (Figure 2 ) CyA absorption ceases after 4 h when given alone or during erythromycin administration. Thus erythromycin affects the rate but not the time-course of the absorption process. This observation raises the possibility that there is a limited period or 'window' for CyA absorption.
Erythromycin was administered 3 h before CyA which rules out the possibility of a physical interaction between erythromycin and CyA in the gut, as by this time all erythromycin is absorbed (Ludden, 1985) . Moreover, Gonwa et al. (1986) observed that even after intravenous administration erythromycin increases the blood CyA concentration when CyA is given orally. Perhaps erythromycin aids in the dissolution of CyA. CyA has a very low aqueous solubility, is administered in a vegetable oil, and the oil and probably the CyA must dissolve to be absorbed. Moreover, bile salts, which form micelles that aid fat dissolution and are essential for efficient fat absorption, also appear to be essential for CyA absorption (Andrews et al., 1985) . Although there are no published data of the effect of erythromycin per se on the biliary system, some salts of erythromycin are reported to be hepatotoxic (Ludden, 1985) .
Drugs that affect gastrointestinal function also appear to alter the absorption of CyA. For example, metoclopramide, which enhances gastric motility, causes an increase in CyA AUC after oral CyA administration (Wadhwa et al., 1987b) . Despite a large variability in the observations, making it difficult to draw any firm conclusion, the data do seem to indicate that metoclopramide increases CyA absorption. In addition, perhaps erythromycin affects the intestinal permeability to CyA, although there is no information regarding this effect.
Although the current data, for both unchanged drug and metabolite 17, are internally consistent, pointing to erythromycin acting primarily by increasing the absorption of CyA, the mean bioavailability of CyA in the control phase, of 36%, in broad agreement in findings of other investigators (Ptachcinski et al., 1986) , contrasts with our earlier findings of a value closer to 70% in other renal transplant patients (Gupta et al., 1987a) . We have, as yet, been unable to reconcile these differences. We have checked carefully all aspects of methodology and can see no reason for this discrepancy. The only noticeable difference is that our earlier findings were in renal transplant patients studied within days of transplantation whereas the patients participating in the current study had been receiving CyA for 6-12 months. We are conducting additional studies to explore this facet.
